{"id":"W2911812451","doi":"10.1056/nejmoa1816047","title":"Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2550,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Jewish General Hospital; BC Cancer Agency","funders":"National Cancer Institute; Merck; Pfizer","keywords":"Axitinib; Avelumab; Sunitinib; Renal cell carcinoma; Medicine; Internal medicine; Oncology; Carcinoma; Urology; Immunotherapy; Nivolumab; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001154011,0.0004188001,0.001462035,0.0003059807,0.000176489,0.0003994693,0.0004028499,0.0004177236,0.003106541],"category_scores_gemma":[0.001334935,0.0001759897,0.0008689418,0.0002354584,0.0002860583,0.0003603165,0.0002148615,0.0008617206,0.0003106579],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005132794,"about_ca_system_score_gemma":0.0006442732,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003298309,"about_ca_topic_score_gemma":0.001127347,"domain_scores_codex":[0.9995993,0.0002059632,0.00004331644,0.00006026017,0.00004975944,0.00004135578],"domain_scores_gemma":[0.9993765,0.0002423105,0.0001534475,0.00002093452,0.00002062459,0.0001862521],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8226693,0.005430748,0.005737685,0.00106664,0.001962478,0.00009461273,0.00006931368,0.003282338,0.01398942,0.0002506611,0.001543101,0.1439036],"study_design_scores_gemma":[0.4779121,0.4636865,0.03449835,0.0001788495,0.002710008,0.0007539539,0.00007305115,0.006341894,0.008041523,0.0006695369,0.005088679,0.00004552916],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9898573,0.007742775,0.0003063481,0.0003077087,0.0001877493,0.0002488396,0.0001924924,0.00003900138,0.001117863],"genre_scores_gemma":[0.9964289,0.002037987,0.0004515696,0.0001316964,0.0001667438,0.0001540708,0.0001439399,0.000003727302,0.0004814531],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003106541,"threshold_uncertainty_score":0.01039237,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03480851642747787,"score_gpt":0.2891911489677947,"score_spread":0.2543826325403168,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}